Xeris Biopharma Holdings, Inc. $XERS Stake Raised by Knott David M Jr

Knott David M Jr boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 9.3% during the first quarter, Holdings Channel.com reports. The institutional investor owned 1,060,000 shares of the company’s stock after buying an additional 90,000 shares during the period. Xeris Biopharma accounts for 3.6% of Knott David M Jr’s investment portfolio, making the stock its 6th largest holding. Knott David M Jr’s holdings in Xeris Biopharma were worth $6,148,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in XERS. Sei Investments Co. boosted its position in Xeris Biopharma by 45.0% in the 1st quarter. Sei Investments Co. now owns 579,210 shares of the company’s stock valued at $3,359,000 after buying an additional 179,863 shares during the period. Cetera Investment Advisers increased its position in shares of Xeris Biopharma by 14.9% during the first quarter. Cetera Investment Advisers now owns 44,397 shares of the company’s stock worth $258,000 after acquiring an additional 5,750 shares during the period. AlphaCentric Advisors LLC increased its position in shares of Xeris Biopharma by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after acquiring an additional 2,494 shares during the period. KBC Group NV acquired a new stake in shares of Xeris Biopharma in the first quarter valued at $27,000. Finally, Swiss National Bank raised its stake in shares of Xeris Biopharma by 3.1% in the first quarter. Swiss National Bank now owns 328,300 shares of the company’s stock valued at $1,904,000 after acquiring an additional 9,900 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Up 0.4%

Shares of NASDAQ XERS opened at $8.41 on Friday. The business has a 50-day moving average of $7.25 and a two-hundred day moving average of $6.75. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 140.17 and a beta of 0.62. Xeris Biopharma Holdings, Inc. has a 1 year low of $4.87 and a 1 year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The business had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. On average, analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Xeris Biopharma currently has an average rating of “Hold” and an average price target of $10.80.

Insider Transactions at Xeris Biopharma

In related news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the transaction, the director directly owned 126,500 shares of the company’s stock, valued at $770,385. This represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dawn Halkuff sold 20,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $121,800.00. Following the completion of the transaction, the director owned 95,000 shares in the company, valued at $578,550. This represents a 17.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 251,500 shares of company stock valued at $1,846,457 over the last three months. 4.35% of the stock is owned by corporate insiders.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.